Sarepta Therapeutics options activity surges as stock jumps nearly 10% and volatility spikes

Sarepta Therapeutics attracted strong market attention on Wednesday after both its stock and options activity surged sharply during intraday trading.

Shares of the biotech company climbed nearly 10% to around 17.30 dollars, while options volume spiked well above normal levels, signaling increased speculative interest in the name.

The move came alongside a clear imbalance in trading activity, with call options overwhelmingly dominating puts.

Options trading in Sarepta Therapeutics hits unusual levels

Total options volume reached more than 5,000 contracts in early trading, a significant jump compared to recent averages.

Call options accounted for the vast majority of activity, with over 5,200 contracts traded, while put volume remained relatively low at just under 100 contracts. This heavy skew toward calls suggests that traders were positioning for continued upside in the stock rather than protection against downside risk.

A large portion of activity centered on the July 17, 2026 20 dollar call strike, which alone represented more than 4,000 contracts. The concentration in a single strike highlights how focused the market positioning has become around a specific upside scenario.

Volatility spikes as investors reposition around biotech outlook

Alongside the surge in options activity, Sarepta’s implied volatility also moved higher.

The company’s three month volatility jumped by nearly 8 percentage points, reaching around 75 percent. That level reflects heightened uncertainty about future price movement and increased demand for options-based exposure.

At the same time, the options skew also widened slightly, indicating a growing premium for calls relative to puts. This often happens when traders expect stronger upward moves or are speculating on potential positive catalysts.

In biotech stocks, volatility shifts like this are often tied to expectations around clinical data, regulatory updates, or strategic developments, even if no immediate announcement has been made.

Sarepta stock rally adds to speculative momentum

The spike in derivatives activity coincided with a strong rally in the underlying stock. Sarepta shares rose sharply during the session, extending recent momentum and pushing the stock back into focus for short term traders.

While the fundamental catalyst behind the move was not immediately clear, the combination of rising stock price, heavy call buying, and increased volatility suggests that sentiment shifted quickly during the session.

For traders, the key takeaway is the level of positioning change happening in a short window. The sharp rise in call volume indicates that investors are increasingly betting on continued strength or anticipating a near term catalyst that could drive further gains.

Whether that momentum continues will likely depend on upcoming news flow and broader risk appetite in biotech markets, but for now, Sarepta has become one of the most actively watched options names of the day.